Table 1 Improvements in AEOL-10150 regarding antiradiation diseases released by Aeolus Pharmaceuticals
From: Improvements in SOD mimic AEOL-10150, a potent broad-spectrum antioxidant
Time (M/D/Y) | Contents |
|---|---|
04/15/2008 | AEOL-10150 protects lungs against fractionated radiation damage and inhibits angiogenesis and inflammation |
07/06/2009 | AEOL-10150 significantly improves survival in mice exposed to radiation when administered after exposure |
09/08/2009 | Initiates study of AEOL-10150 as a treatment against radiation exposure in nonhuman primates |
11/17/2009 | Duke University initiates study of AEOL-10150 to observe the compound’s activity protecting healthy tissue in mice receiving chemotherapy and radiation for non-small-cell lung cancer |
04/12/2010 | Proclaims the initiation of a second study of AEOL-10150 as a medical treatment against GI acute radiation syndrome funded by the NIH’s National Institute for Allergy and Infectious Diseases |
11/02/2010 | AEOL-10150 improves survival in nonhuman primates exposed to lethal doses of radiation |
02/08/2012 | AEOL-10150 protects lung tissue from radiation by regulating PTEN levels and inhibiting oxidative stress and apoptosis |
06/01/2012 | AEOL-10150 alleviates lung damage after Neupogen treatment following radiation exposure |
09/17/2013 | BARDA exercises $6.0Â mm in additional contract funding to develop AEOL-10150 as countermeasure against acute radiation syndrome |
10/29/2013 | AEOl-10,150 significantly increases survival and protects lungs in mice exposed to lethal radiation |
08/20/2014 | Aeolus files an investigational new drug application with the FDA to enable the initiation of human safety studies for the development of AEOL-10150 as a medical treatment against lung damage from radiation exposure |
09/04/2014 | Proclaims positive results from a study showing AEOL-10150 doubles the survival rate following lung damage caused by acute radiation exposure |
05/04/2015 | Aeolus proclaims complete results from a successful study showing AEOL-10150 doubles survival rate following lung damage from acute radiation exposure |
06/26/2015 | BARDA exercises $3 mm in additional contract funding for the development of AEOL −10,150 as a countermeasure to acute radiation syndrome |
06/08/2017 | FDA fast track designation granted to AEOL-10150 for treatment of patients with lung acute radiation syndrome following a radiological or nuclear event |